TrialNature communications2025

Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trial.

Jean E Abraham et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.